The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Dosimetry in patients with B-cell lymphoma treated with [90Y]ibritumomab tiuxetan or [131I]tositumomab.

På svenska

Author

Summary, in English

Radioimmunotherapy involves the use of radiolabeled monoclonal antibodies (MAbs) to treat malignancy. The therapeutic effect is determined by the radiopharmaceutical, the radiation absorbed dose and previous treatments. There are currently two approved radiopharmaceuticals for the treatment of B-cell lymphoma - the 90Y-labeled ibritumomab and the 131I-labeled tositumomab. Both are directed against CD20, albeit not against the same epitope. This paper summarizes current results of dose-responses for normal tissues and tumours of [131I]tositumomab and [90Y]ibritumomab tiuxetan, discusses them in the context of dosimetry methods used and highlights the assumptions being made in the different dosimetry methodologies. Moreover, we wish to point at the possibility of performing low-cost therapy bremsstrahlung imaging for [90Y]ibritumomab tiuxetan to confirm biodistribution, and possibly also for dosimetric calculations.

Department/s

Publishing year

2011

Language

English

Pages

126-154

Publication/Series

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volume

55

Issue

2

Document type

Journal article

Publisher

Edizioni Minerva Medica

Topic

  • Radiology, Nuclear Medicine and Medical Imaging
  • Cancer and Oncology

Keywords

  • Lymphoma
  • Dosimetry
  • Antibodies
  • monoclonal
  • Radioimmunotherapy

Status

Published

ISBN/ISSN/Other

  • ISSN: 1824-4785